Table 2 Relative risk (rate ratio) of a second cancer of selected sites among thrombosis cancer patients and control cancer patients during 2–23 years of follow-up
From: The risk of a second cancer after hospitalisation for venous thromboembolism
VTE cancer cohort, N =3339 | Control cancer cohort, N =21 713 | ||||
|---|---|---|---|---|---|
Sites of second cancer (ICD-7 code) a | No. of events | No./1000 person-year | No. of events | No./1000 person-year | Relative risk (95% CI) |
All | 238 | 18.2 | 1610 | 15.8 | 1.1 (1.0–1.3) |
Oesophagus (150) | 4 | 0.3 | 22 | 0.2 | 1.4 (0.5–4.0) |
Colon, rectum (153, 154) | 47 | 3.6 | 254 | 2.5 | 1.4 (1.1–2.0) |
Liver, primary, gall bladder, pancreas (155.0, 155.1, 157) | 11 | 0.8 | 89 | 0.9 | 0.9 (0.5–1.8) |
Lung, primary (162) | 30 | 2.3 | 276 | 2.7 | 0.8 (0.6–1.2) |
Breast (170) | 29 | 2.2 | 181 | 1.8 | 1.3 (0.9–1.9) |
Ovary (175) | 3 | 0.2 | 33 | 0.3 | 0.7 (0.2–2.3) |
Prostate (177) | 30 | 2.3 | 121 | 1.2 | 1.8 (1.2–2.7) |
Kidney, bladder (180, 181) | 22 | 1.7 | 194 | 1.9 | 0.9 (0.6–1.3) |
Lymphatic and haematological (200–205) | 18 | 1.4 | 129 | 1.3 | 1.1 (0.7–1.8) |
